Name
CORYFIN SEDATIVE FLUIDIFYING 20 mg/g + 1 mg/g syrup
Potassium sulfoguaiacolate + dextromethorphan hydrobromide
What is it and what is it for?
Coryfin Sedative Fluidifier contains dextromethorphan hydrobromide, a cough suppressant, and potassium sulfoguaiacolate, an expectorant.
This medicine is indicated for the treatment of cough symptoms.
Contact your doctor if you do not feel better or if you feel worse after 7 days.
What you need to know before taking the medicine
This medicine can lead to addiction. Therefore, treatment should be short-term.
Do not use Coryfin Sedative Fluidifier
- if you are allergic to dextromethorphan or potassium sulfoguaiacolate or any of the other ingredients of this medicine (listed in section 6);
- if you are taking or have taken up to 2 weeks ago antidepressants (medicines used for depression) (see “Other medicines and Coryfin Sedative Fluidifier”);
- if you suffer from asthma (constriction and inflammation of the bronchi);
- if you suffer from a respiratory disease characterised by bronchial obstruction and inflammation of the bronchi and lungs (chronic obstructive pulmonary disease);
- if you have a lung infection (pneumonia);
- if you have breathing problems (difficulty or depression in breathing);
- if you suffer from heart or blood vessel problems (cardiovascular disease);
- if you have high blood pressure (hypertension);
- if you have an overactive thyroid (hyperthyroidism);
- if you suffer from a disease that causes increased pressure in the eye and vision problems (glaucoma);
- if you have an enlarged prostate (prostatic hypertrophy);
- if you have narrowing of the stomach or intestines (gastrointestinal tract strictures);
- if you suffer from narrowing of the urinary or genital tract (urogenital stenosis);
- if you suffer from a disease that causes loss of consciousness and violent involuntary muscle contractions (epilepsy);
- if you suffer from serious liver disease;
- if you are pregnant, especially in the first trimester, or are breastfeeding (see “Pregnancy and breastfeeding”);
- if the child to be treated is under two years old.
Warnings and precautions
Talk to your doctor or pharmacist before using Coryfin Sedative Fluidifier:
- if you have a history of drug or narcotic abuse (psychoactive substances capable of altering the psycho-physical state);
- if the subject to be treated is an adolescent or a young adult;
- if you have a chronic or persistent cough (for example due to smoking and some respiratory diseases such as emphysema/asthma);
- if the cough is accompanied by other symptoms such as fever, appearance of a skin rash, headache, nausea and vomiting;
- if your cough is irritating with abundant mucus production;
- if you suffer from liver or kidney problems;
- if you are taking medicines containing buprenorphine. Using these medicines together with Coryfin Sedative Fluidifier can lead to serotonin syndrome, a condition that can be fatal (see “Other medicines and Coryfin Sedative Fluidifier”).
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects may occur with the use of this medicine with an unknown frequency (the frequency cannot be estimated from the available data):
• allergic (hypersensitivity) reactions including anaphylactic reaction (a serious, rapidly developing and potentially fatal allergic reaction), angioedema (swelling of the skin or mucous membranes), hives, itching, rash (skin eruption) and erythema (redness of the skin);
• hallucinations (seeing or hearing things that are not there);
• drowsiness, dizziness;
• gastrointestinal disorders (stomach and intestinal disorders), nausea, vomiting and reduced appetite;
• fatigue, fever.
Reporting of side effects
If you experience any side effects, including any not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at: https://www.aifa.gov.it/content/segnalazionireazioni-avverse .
By reporting side effects you can help provide more information on the safety of this medicine.